U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H7NO3S
Molecular Weight 125.147
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAURINE

SMILES

NCCS(O)(=O)=O

InChI

InChIKey=XOAAWQZATWQOTB-UHFFFAOYSA-N
InChI=1S/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)

HIDE SMILES / InChI

Molecular Formula C2H7NO3S
Molecular Weight 125.147
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 | https://www.ncbi.nlm.nih.gov/pubmed/26208967

Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.

Originator

Curator's Comment: Taurin was first isolated from ox bile in 1827.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
406.0 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TAURINE

Approved Use

Taking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year.
Palliative
TAURINE

Approved Use

Taking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis.
Preventing
URSA Complex

Approved Use

Taurine is a component of energy drinks used for relieving of fatigue
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Amino acids as biochemical markers in epidemic and endemic optic neuropathies].
1998
Taurine attenuates fanconi syndrome induced by ifosfamide without compromising its antitumor activity.
1998
Glutamate and taurine are increased in ventricular cerebrospinal fluid of severely brain-injured patients.
1999 Feb
Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid.
2000 Jun
The involvement of caspases in the CD95(Fas/Apo-1)- but not swelling-induced cellular taurine release from Jurkat T-lymphocytes.
2000 May
Calcium-mediated transductive systems and functionally active gap junctions in astrocyte-like GL15 cells.
2001
The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography.
2001
Isolation and characterization of an alpha 2-type zebrafish glycine receptor subunit.
2001
New developments in the pharmacotherapy of alcohol dependence.
2001
Oxygen metabolites in immune- stimulated ion transport in rat colon: modulation by taurine.
2001
Low taurine, gamma-aminobutyric acid and carnosine levels in plasma of diabetic pregnant rats: consequences for the offspring.
2001
Transport of L-carnitine in isolated cerebral cortex neurons.
2001 Apr
Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits.
2001 Apr
Fertilizability and developmental capacity of bovine oocytes cultured individually in a chemically defined maturation medium.
2001 Apr 15
Endogenous glutamate-taurine interaction in striatum and nucleus accumbens of the freely moving rat: studies during the normal process of aging.
2001 Apr 15
Reduction of phospholemman expression decreases osmosensitive taurine efflux in astrocytes.
2001 Apr 23
Energy-related metabolites during and after induced myocardial infarction with special emphasis on the reperfusion injury after extracorporeal circulation.
2001 Feb
Aging-induced changes in 24-h rhythms of mitogenic responses, lymphocyte subset populations and neurotransmitter and amino acid content in rat submaxillary lymph nodes during Freund's adjuvant arthritis.
2001 Feb
Real-time, two-dimensional visualization of ischaemia-induced glutamate release from hippocampal slices.
2001 Feb
Taurine - monograph.
2001 Feb
Hamster sperm glycine receptor: evidence for its presence and involvement in the acrosome reaction.
2001 Feb
An in vivo eyecup preparation for the rat.
2001 Feb 15
Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients.
2001 Jan
MR diffusion imaging and 1H spectroscopy in a child with medulloblastoma. A case report.
2001 Jan
Taurine modulates catalase, aldehyde dehydrogenase, and ethanol elimination rates in rat brain.
2001 Jan-Feb
Role of taurine in preventing acetaminophen-induced hepatic injury in the rat.
2001 Jun
Two-voxel localization sequence for in vivo two-dimensional homonuclear correlation spectroscopy.
2001 Mar
Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation.
2001 Mar 16
Spinal taurine levels are increased 7 and 30 days following methylprednisolone treatment of spinal cord injury in rats.
2001 Mar 2
Intrathecal magnesium sulfate attenuates algogenic behavior and spinal amino acids release after kainic acid receptor activation in rats.
2001 Mar 30
Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings.
2001 Mar-Apr
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials.
2001 May
The influence of plasma on the disinfecting activity of the new antimicrobial agent N-chlorotaurine-sodium in comparison with chloramine T.
2001 May
High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1.
2001 May
Patents

Sample Use Guides

Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration: Oral
In Vitro Use Guide
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:30:13 UTC 2023
Edited
by admin
on Wed Jul 05 22:30:13 UTC 2023
Record UNII
1EQV5MLY3D
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
TAURINE
FHFI   INCI   INN   MART.   MI   USP   USP-RS   VANDF   WHO-DD  
INCI   INN  
Official Name English
TAURINE [JAN]
Common Name English
TAURINE [MI]
Common Name English
taurine [INN]
Common Name English
TAURINE [USP-RS]
Common Name English
TAURINE [FHFI]
Common Name English
AMINOETHYLSULFONIC ACID
JAN  
Systematic Name English
AMINOETHYLSULFONIC ACID [JAN]
Common Name English
Taurine [WHO-DD]
Common Name English
NSC-32428
Code English
TAURINE [MART.]
Common Name English
Ethanesulfonic acid, 2-amino-
Common Name English
FEMA NO. 3813
Code English
TAURINE [INCI]
Common Name English
TAURINE [VANDF]
Common Name English
TAURINE [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
LOINC 26896-1
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 15208-2
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 56985-5
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
NCI_THESAURUS C45564
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 2981-9
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 15140-7
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 25985-3
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 20657-3
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
JECFA EVALUATION TAURINE
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 30563-1
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 17679-2
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 2979-3
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
NCI_THESAURUS C68442
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
DSLD 2060 (Number of products:2643)
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 2980-1
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 13415-5
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
FDA ORPHAN DRUG 298709
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 17678-4
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 44411-7
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 28595-7
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 27310-2
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 13814-9
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 25138-9
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 26614-8
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 2982-7
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 25533-1
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 15136-5
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
CFR 21 CFR 573.980
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
DSLD 504 (Number of products:17)
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 33214-8
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 32271-9
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 47782-8
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
LOINC 9324-5
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
Code System Code Type Description
HSDB
8167
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
DRUG BANK
DB01956
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
CAS
107-35-7
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
SMS_ID
100000082407
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
ECHA (EC/EINECS)
203-483-8
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
FDA UNII
1EQV5MLY3D
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
WIKIPEDIA
TAURINE
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
CHEBI
15891
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
RXCUI
10337
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY RxNorm
RXCUI
1431306
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
EPA CompTox
DTXSID3021304
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
DAILYMED
1EQV5MLY3D
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
ChEMBL
CHEMBL239243
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
GRAS Notification (GRN No.)
586
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
NSC
32428
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
CHEBI
507393
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
PUBCHEM
1123
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
EVMPD
SUB10836MIG
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
RS_ITEM_NUM
1643361
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
DRUG CENTRAL
4486
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
MERCK INDEX
M10481
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C61962
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
INN
6171
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
MESH
D013654
Created by admin on Wed Jul 05 22:30:13 UTC 2023 , Edited by admin on Wed Jul 05 22:30:13 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
SUB_CONCEPT->SUBSTANCE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE
Related Record Type Details
ACTIVE MOIETY